Gilead Sciences, Inc.
$170
−0.21% day
Gilead Sciences is a US drugmaker built on antivirals, and among the largest suppliers of HIV medicines, including the twice-yearly prevention shot lenacapavir. Its shares turn on how long those drugs hold their pricing and on what follows them.
Nov 2 · $170.33 · +17.8% vs the window’s open
the numbers21
| when | value | change |
|---|---|---|
| Oct 5 | $144.63 | |
| Oct 6low | $144.23 | −0.3% |
| Oct 7 | $146.85 | +1.8% |
| Oct 8 | $147.10 | +0.2% |
| Oct 9 | $151.17 | +2.8% |
| Oct 12 | $150.43 | −0.5% |
| Oct 13 | $147.92 | −1.7% |
| Oct 14 | $153.54 | +3.8% |
| Oct 15 | $157.37 | +2.5% |
| Oct 16 | $156.19 | −0.7% |
| Oct 19 | $153.07 | −2.0% |
| Oct 20 | $156.51 | +2.2% |
| Oct 21 | $153.57 | −1.9% |
| Oct 22 | $157.19 | +2.4% |
| Oct 23 | $156.04 | −0.7% |
| Oct 26 | $158.69 | +1.7% |
| Oct 27 | $159.08 | +0.2% |
| Oct 28 | $159.20 | +0.1% |
| Oct 29 | $165.61 | +4.0% |
| Oct 30high | $170.68 | +3.1% |
| Nov 2latest | $170.33 | −0.2% |
Lately
A generic version of Gilead's twice-yearly HIV-prevention shot, lenacapavir, was cleared for low-income countries at an expected $40 a year instead of $28,218. That news came after the rise, and nothing in the input explains the share price.